These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 27185625

  • 1. RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors.
    van Mechelen L, Luytjes W, de Haan CA, Wicht O.
    Antiviral Res; 2016 Aug; 132():1-5. PubMed ID: 27185625
    [Abstract] [Full Text] [Related]

  • 2. In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.
    van Erp EA, van Kasteren PB, Guichelaar T, Ahout IML, de Haan CAM, Luytjes W, Ferwerda G, Wicht O.
    J Virol; 2017 Nov 01; 91(21):. PubMed ID: 28794038
    [Abstract] [Full Text] [Related]

  • 3. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.
    Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF.
    J Mol Biol; 2005 Jul 01; 350(1):126-44. PubMed ID: 15907931
    [Abstract] [Full Text] [Related]

  • 4. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 5. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.
    Jacobino SR, Nederend M, Reijneveld JF, Augustijn D, Jansen JHM, Meeldijk J, Reiding KR, Wuhrer M, Coenjaerts FEJ, Hack CE, Bont LJ, Leusen JHW.
    MAbs; 2018 Apr 04; 10(3):453-462. PubMed ID: 29553863
    [Abstract] [Full Text] [Related]

  • 6. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.
    Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L.
    Proc Natl Acad Sci U S A; 2014 Apr 22; 111(16):5992-7. PubMed ID: 24711420
    [Abstract] [Full Text] [Related]

  • 7. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
    Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.
    J Infect Dis; 2011 Mar 01; 203(5):674-82. PubMed ID: 21208913
    [Abstract] [Full Text] [Related]

  • 8. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.
    Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE.
    Virology; 2014 Apr 01; 454-455():139-44. PubMed ID: 24725940
    [Abstract] [Full Text] [Related]

  • 9. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.
    Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL.
    J Virol; 2008 Dec 01; 82(24):12191-204. PubMed ID: 18842713
    [Abstract] [Full Text] [Related]

  • 10. Binding and Neutralizing Capacity of Respiratory Syncytial Virus (RSV)-Specific Recombinant IgG Against RSV in Human Milk, Gastric and Intestinal Fluids from Infants.
    Demers-Mathieu V, Lueangsakulthai J, Qu Y, Scottoline BP, Dallas DC.
    Nutrients; 2020 Jun 27; 12(7):. PubMed ID: 32605037
    [Abstract] [Full Text] [Related]

  • 11. Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV.
    Nederend M, van Stigt AH, Jansen JHM, Jacobino SR, Brugman S, de Haan CAM, Bont LJ, van Neerven RJJ, Leusen JHW.
    Front Immunol; 2020 Jun 27; 11():1701. PubMed ID: 32849597
    [Abstract] [Full Text] [Related]

  • 12. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
    Bian C, Liu S, Liu N, Zhang G, Xing L, Song Y, Duan Y, Gu H, Zhou Y, Zhang P, Li Z, Zhang K, Wang Z, Zhang S, Wang X, Yang P.
    Antiviral Res; 2014 Apr 27; 104():110-7. PubMed ID: 24509239
    [Abstract] [Full Text] [Related]

  • 13. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
    Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L.
    J Infect Dis; 2001 Aug 01; 184(3):350-4. PubMed ID: 11443562
    [Abstract] [Full Text] [Related]

  • 14. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
    Chen Z, Zhang L, Tang A, Callahan C, Pristatsky P, Swoyer R, Cejas P, Nahas D, Galli J, Cosmi S, DiStefano D, Hoang VM, Bett A, Casimiro D, Vora KA.
    PLoS One; 2016 Aug 01; 11(6):e0156798. PubMed ID: 27258388
    [Abstract] [Full Text] [Related]

  • 15. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T, Cayatte C, Roe TL, Speer SD, Ji H, Machiesky L, Zhang T, Wilkins D, Tuffy KM, Kelly EJ.
    Front Immunol; 2023 Aug 01; 14():1283120. PubMed ID: 37901217
    [Abstract] [Full Text] [Related]

  • 16. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM.
    J Infect Dis; 2004 Sep 01; 190(5):975-8. PubMed ID: 15295704
    [Abstract] [Full Text] [Related]

  • 17. Structural basis of respiratory syncytial virus neutralization by motavizumab.
    McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD.
    Nat Struct Mol Biol; 2010 Feb 01; 17(2):248-50. PubMed ID: 20098425
    [Abstract] [Full Text] [Related]

  • 18. A review of palivizumab and emerging therapies for respiratory syncytial virus.
    Shadman KA, Wald ER.
    Expert Opin Biol Ther; 2011 Nov 01; 11(11):1455-67. PubMed ID: 21831008
    [Abstract] [Full Text] [Related]

  • 19. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.
    Sawada A, Nakayama T.
    Microbiol Immunol; 2016 Apr 01; 60(4):234-42. PubMed ID: 26865035
    [Abstract] [Full Text] [Related]

  • 20. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S.
    Virology; 2008 Aug 15; 378(1):79-85. PubMed ID: 18556039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.